Skip to main content
Biocon Ltd. logo

Biocon Ltd. — Investor Relations & Filings

Ticker · BIOCON ISIN · INE376G01013 LEI · 335800NK3L7QCHLOC198 BSE.NS Manufacturing
Open in API
Filings indexed 1,693 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS BIOCON

About Biocon Ltd.

https://www.biocon.com/

Biocon Ltd. is a global biopharmaceutical company focused on developing innovative therapies for chronic conditions such as diabetes, oncology, and autoimmune diseases. The company specializes in the research, development, and manufacture of high-quality biosimilars, generic active pharmaceutical ingredients (APIs), and novel biologics. Its portfolio includes recombinant human insulin, insulin analogs, and monoclonal antibodies. Biocon leverages an integrated business model encompassing advanced research and development, large-scale manufacturing, and global commercialization. By prioritizing affordable innovation, the company aims to enhance access to life-saving treatments across international markets, including the United States, Europe, and emerging economies. Its technical expertise in microbial fermentation and complex protein engineering supports a robust pipeline of complex therapeutics designed to address unmet medical needs.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 75% confidence The document is a compliance letter under Regulation 30 of SEBI LODR sent to BSE and NSE, notifying a reminder to shareholders to claim unclaimed dividends before transfer to the IEPF. It does not announce a new dividend payment nor contain substantive financial statements but serves as a regulatory announcement of a corporate action. This falls under the general “Regulatory Filings” category rather than a specific dividend notice or financial report.
2026-05-21 English
Reminder Letter to shareholders to claim unclaimed dividends
Regulatory Filings Classification · 85% confidence The document is a formal reminder letter sent under SEBI LODR Regulation 30 to shareholders to claim unclaimed dividends and avoid transfer of their shares to the IEPF. It does not announce a new dividend payment but is a compliance disclosure under listing regulations. This falls under general regulatory announcements that do not fit other specific categories, so it is classified as a Regulatory Filing (RNS).
2026-05-21 English
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Regulatory Filings Classification · 82% confidence The document is a notice sent to stock exchanges under SEBI Listing Regulations informing about the schedule of management meetings with analysts/institutional investors. It does not contain slides or substantive financial results, nor is it an AGM presentation, earnings release, or a transcript. It’s a compliance disclosure with no substantive report attached and thus falls under general Regulatory Filings.
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a routine stock exchange disclosure under SEBI Listing Regulations, notifying the schedule of meetings with analysts/institutional investors. It does not contain financial results, presentations, or actual reports—it is a regulatory compliance announcement. This fits the catch‐all “Regulatory Filings” category (RNS).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 92% confidence The document is clearly the full text transcript of Biocon Limited’s Q4 FY26 earnings conference call, including prepared remarks, speaker lists, and Q&A format. It is not just an earnings release summary or investor presentation, but the verbatim call transcript, which matches the definition of a Call Transcript (CT).
2026-05-14 English
Transcript of Earnings Call Q4 FY 26
Call Transcript Classification · 95% confidence The document is headed “Transcript of Earnings Call Q4 FY26,” contains a letter to stock exchanges enclosing the full transcript, and includes speaker lists, prepared remarks, and Q&A from the earnings conference call. This clearly matches the definition of a full call transcript of a company conference call. Therefore, the appropriate classification is CT.
2026-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.